Inventiva will present updates related to its MASH clinical trial therapy programme at several healthcare investor conferences in March. The clinical-stage biopharmaceutical company is developing lanifibranor, an investigational oral therapy currently being evaluated in a Phase 3 study.
MASH clinical trial therapy to be highlighted at investor conferences
Inventiva confirmed that its leadership team will participate in presentations and meetings during several healthcare investor conferences in the United States during March.
Events include the TD Cowen Annual Health Care Conference in Boston, the Leerink Global Healthcare Conference in Miami, the Barclays Global Healthcare Conference and the UBS Biotech Conference.
Understanding the growing focus on MASH clinical trial therapy
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with metabolic disorders such as obesity and type 2 diabetes. The condition can lead to liver inflammation, fibrosis and potentially cirrhosis.
Research into MASH clinical trial therapy programmes has accelerated in recent years as pharmaceutical companies explore treatments capable of slowing or reversing disease progression.
Lanifibranor under evaluation in Phase 3 clinical trial
Inventiva is currently evaluating lanifibranor, a pan-PPAR agonist designed to address several biological pathways involved in metabolic liver disease. The therapy is being studied in the Phase 3 NATiV3 clinical trial.
The trial is assessing the treatment in adult patients with MASH, a condition that affects a growing number of patients globally.
Company engages investors on development strategy
Investor conferences provide opportunities for biotechnology companies to present clinical development updates and discuss strategic priorities with investors and industry stakeholders.
Inventiva’s presentations will be accessible through the investor presentations section of the company’s website.
Further coverage of biotechnology and pharmaceutical development can be found in the Pharmaceuticals section of Life Sciences Global News.
